Emergent BioSolutions (EBS) said Monday that the Biomedical Advanced Research and Development Authority has awarded a $50 million option to the company's existing contract for the purchase of Cyfendus, or Anthrax vaccine adsorbed, adjuvanted.

Deliveries are set to start this year and finish by April, the company said.

This follows a previous $30 million contract modification to supply the vaccine this year. The project is backed by federal funds from the US Department of Health and Human Services, the company said.

Cyfendus was approved by the US Food and Drug Administration in July 2023 as a two-dose vaccine for post-exposure anthrax prevention in people 18 to 65 years old.

Shares of Emergent BioSolutions rose more than 4% in recent trading.

Price: 8.85, Change: +0.37, Percent Change: +4.36